NVP Healthcare
CompanySouth Korea
NVP Healthcare develops one asset, in phase 1 (NVP-1205 in dyslipidemia). Mostly small molecule acting on lipid and ceramide metabolism, HMGCR and NPC1L1; based in South Korea.
- 1
- Asset
- Furthest stage
- Phase 1
- 2
- Trials
- 0
- Signals
Pipeline
1Combination inhibiting HMG-CoA reductase and NPC1L1 for lipid lowering.
Phase 1, Small molecule, Lipid and ceramide metabolism, HMGCR, dyslipidemia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials2
- Similar companies6